Abstract |
Aventis Pharma (formerly Hoechst Marion Roussel) is developing insulin glulisine, a fast-acting insulin analog, for the potential treatment of hyperglycemia in both type 1 and 2 diabetes. Aventis has submitted an NDA and an MAA to the FDA and the EMEA, respectively.
|
Authors | Daniela Barlocco |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 4
Issue 10
Pg. 1240-4
(Oct 2003)
ISSN: 1472-4472 [Print] England |
PMID | 14649217
(Publication Type: Journal Article, Review)
|
Chemical References |
- Hypoglycemic Agents
- Insulin
- insulin glulisine
|
Topics |
- Animals
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Diabetes Mellitus, Type 1
(drug therapy)
- Diabetes Mellitus, Type 2
(drug therapy)
- Humans
- Hypoglycemic Agents
(adverse effects, chemical synthesis, pharmacokinetics, therapeutic use)
- Insulin
(adverse effects, analogs & derivatives, chemical synthesis, pharmacokinetics, therapeutic use)
- Structure-Activity Relationship
|